GATA-3 immunohistochemistry in the differential diagnosis of Adenocarcinoma of the urinary bladder

American Journal of Surgical Pathology

Volumn 37, Issue 11, 2013, Pages 1756-1760

  Ellis, Carla L ^a   Chang, Alex G ^a   Cimino Mathews, Ashley ^a   Argani, Pedram ^a   Youssef, Ramy F ^b   Kapur, Payal ^b   Montgomery, Elizabeth A ^a   Epstein, Jonathan I ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

bladder adenocarcinoma; GATA 3; signet ring cells; urothelium

Indexed keywords

GATA3 PROTEIN, HUMAN; MUCIN; TRANSCRIPTION FACTOR GATA 3; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BIOPSY; BLADDER TUMOR; CHEMISTRY; CYSTECTOMY; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PREDICTIVE VALUE; SIGNET RING CARCINOMA; TISSUE MICROARRAY; UNITED STATES;

ADENOCARCINOMA; ADULT; AGED; BALTIMORE; BIOPSY; CARCINOMA, SIGNET RING CELL; CYSTECTOMY; DIAGNOSIS, DIFFERENTIAL; FEMALE; GATA3 TRANSCRIPTION FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUCINS; PREDICTIVE VALUE OF TESTS; TEXAS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84886399791     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31829cdba7     Document Type: Article

References (17)

1. Higgins JP, Kaygusuz G, Wang L, et al. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol. 2007;31:673-680.
2. Liu H, Shi J, Wilkerson M, et al. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues. A useful immunomarker for breast and urothelial carcinoma. Am J Clin Pathol. 2012;138:57-64.
3. Asselin-Labat ML, Sutherland KD, Barker H, et al. GATA-3 is an essential regulator of mammary gland morphogenesis and luminal cell differentiation. Nat Cell Biol. 2007;9:201-209.
4. Chou J, Provot S, Werb Z, et al. GATA-3 in development and cancer differentiation: cells GATA have it! J Cell Physiol. 2010; 222:42-49.
5. Kouros-Mehr H, Kim JW, Bechis SK, et al. GATA-3 and the regulation of the mammary luminal cell fate. Curr Opin Cell Biol. 2008;20:164-170.
6. Zheng R, Blobel GA. GATA transcription factors and cancer. Genes Cancer. 2010;1:1178-1188.
7. Raspollini MR, Sardi I, Giunti L, et al. Plasmacytoid urothelial carcinoma of the urinary bladder: clinicopathologic, immnuohistochemical, ultrastructural and molecular analysis of a case series. Hum Pathol. 2011;42:1149-1158.
8. Eble JN, Sauter G, Epstein JI. Pathology and Genetics: Tumours of the Urinary System and Male Genital Organs. WHO Classification of Tumours. Lyon: IARC Press; 2004.
9. Epstein JI, Reuter VE, Amin MB. Biopsy Interpretation of the Bladder. Second Edition. Biopsy Interpretation Series. Philadelphia, PA: Lippincott Williams and Wilkins; 2010.
10. Bernstein SA, Reuter VE, Carroll PR, et al. Primary signet-ring cell carcinoma of urinary bladder. Urology. 1988;31:432-436.
11. Poore TE, Egbert B, Jahnke R, et al. Signet ring cell adenocarcinoma of the bladder: linitis plastica variant. Arch Pathol Lab Med. 1981;105:203-204.
12. Chang A, Amin A, Gabrielson E, et al. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus and lung. Am J Surg Pathol. 2012;36: 1472-1476.
13. Zhong M, Gersbach E, Rohan S, et al. Primary adenocarcinoma of the urinary bladder: differential diagnosis and clinical relevance. Arch Pathol Lab Med. 2013;137:371-381.
14. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009;374:239-249.
15. Wright JC. Update in cancer chemotherapy: genitourinary tract cancer, part 1. J Natl Med Assoc. 1987;79:1249-1258.
16. Cimino-Mathews A, Subhawong AP, Illei PB, et al. GATA-3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastaticcarcinomas. Hum Pathol. 2013. [Epub ahead of print].
17. Rao Q, Williamson SR, Lopez-Beltran A, et al. Distinguishing primary adenocarcinoma of the urinary bladder from secondary involvement by colorectal adenocarcinoma: extended immunohistochemical profiles emphasizing novel markers. Mod Pathol. 2013;26:725-732.